Publications for Claes Malm
Co-author map based on ISI articles 2007-

Publications mentioned in social media 7 times*

Keywords

treatment transplantation survival stem risk respectively patients myeloid median marrow leukemia imatinib donor disease conditioning chronic chemotherapy cells blood allogeneic

Journal Articles

Martin Hoglund, Fredrik Sandin, Karin Hellstrom, Mats Bjoreman, Magnus Bjorkholm, Mats Brune, Arta Dreimane, Marja Ekblom, Soren Lehmann, Per Ljungman, Claes Malm, Berit Markevarn, Kristina Myhr-Eriksson, Lotta Ohm, Ulla Olsson-Stromberg, Anders Sjalander, Hans Wadenvik, Bengt Simonsson, Leif Stenke and Johan Richter
  Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry
 
Altmetric usage: 1

  Blood, 2013, 122(7), 1284-1292.
 Web of Science® Times Cited: 3

F Baron, M Labopin, D Niederwieser, S Vigouroux, J J. Cornelissen, Claes Malm, L L. Vindelov, D Blaise, J J W M Janssen, E Petersen, G Socie, A Nagler, V Rocha and M Mohty
  Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation
 
Altmetric usage: 1

  Leukemia, 2012, 26(12), 2462-2468.
 Web of Science® Times Cited: 25

Maciej Machaczka, Jan-Erik Johansson, Mats Remberger, Helene Hallbook, Claes Malm, Vladimir Lj Lazarevic, Anders Wahlin, Hamdy Omar, Gunnar Juliusson, Eva Kimby and Hans Hagglund
  Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?
 
Altmetric usage: 1

  Leukemia and Lymphoma, 2012, 53(9), 1699-1705.
 Web of Science® Times Cited: 5

Arnon Nagler, Myriam Labopin, Avichai Shimoni, Ghulam J Mufti, Jan J Cornelissen, Didier Blaise, Jeroen J W M Janssen, Noel Milpied, Lars Vindelov, Eefke Petersen, John Gribben, Andrea Bacigalupo, Claes Malm, Dietger Niederwieser, Gerard J Socie, Renate Arnold, Paul Brown, Hakan Goker, Vanderson Rocha and Mohamad Mohty
  Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT
 
Altmetric usage: 1

  European Journal of Haematology, 2012, 89(3), 206-213.

Vladimir Lazarevic, Mats Remberger, Hans Hagglund, Gunnar Juliusson, Hamdy Omar, Helene Halbook, Eva Kimby, Claes Malm, Anders Wahlin and Jan-Erik Johansson
  Letter: Long-term survival after allogeneic stem cell transplant for relapsed large B cell lymphomas: a retrospective study
  Leukemia and Lymphoma, 2012, 53(3), 503-505.

J. Abelsson, M. Merup, G. Birgegård, O. WeisBjerrum, L. Brinch, M. Brune, P. Johansson, M. Kauppila, S. Lenhoff, M. Liljeholm, Claes Malm, K. Remes, L. Vindelöv and Björn Andréasson
  The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries
  Bone Marrow Transplantation, 2012, 47(3), 380-386.
 Web of Science® Times Cited: 7

Bengt Simonsson, Tobias Gedde-Dahl, Berit Markevarn, Kari Remes, Jesper Stentoft, Anders Almqvist, Mats Bjoreman, Max Flogegard, Perttu Koskenvesa, Anders Lindblom, Claes Malm, Satu Mustjoki, Kristina Myhr-Eriksson, Lotta Ohm, Anu Rasanen, Marjatta Sinisalo, Anders Sjalander, Ulla Stromberg, Ole Weiss Bjerrum, Hans Ehrencrona, Franz Gruber, Veli Kairisto, Karin Olsson, Fredrik Sandin, Arnon Nagler, Johan Lanng Nielsen, Henrik Hjorth-Hansen and Kimmo Porkka
  Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
 
Altmetric usage: 1

  Blood, 2011, 118(12), 3228-3235.
 Web of Science® Times Cited: 45

Vladimir Lj Lazarevic, Hans Hagglund, Mats Remberger, Anders Wahlin, Helene Hallbook, Gunnar Juliusson, Eva Kimby, Claes Malm, Hamdy Omar and Jan-Erik Johansson
  Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden
  LEUKEMIA and LYMPHOMA, 2011, 52(1), 69-71.

M. Bjorkholm, A.R. Derolf, M. Hultcrantz, S.Y. Kristinsson, C. Ekstrand, L.R. Goldin, B. Andreasson, G. Birgegard, O. Linder, Claes Malm, B. Markevarn, L. Nilsson, J. Samuelsson, F. Granath and O. Landgren
  Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms
 
Altmetric usage: 2

  Journal of Clinical Oncology, 2011, 29(17), 2410-2415.
 Web of Science® Times Cited: 42

V.L. Lazarevic, M. Remberger, H. Hagglund, H. Hallbook, G. Juliusson, E. Kimby, Claes Malm, A. Wahlin, H. Omar and J.-E. Johansson
  Letter: Myeloablative allogeneic stem cell transplantation for lymphoblastic lymphoma in Sweden: A retrospective study
  American Journal of Hematology, 2011, 86(8), 709-710.

U Olsson-Strömberg, M Höglund, M Björkholm, I Braide, K Carlson, G Gahrton, G Grimfors, R Hast, r Lerner, O Linder, P Ljungman, E Löfvenberg, Claes Malm, PG Nilsson, c Paul, s Rodjer, L Stenke, U Tidefeldt, I Turesson, AM Uden, A Wahlin, L Vilén, I Winqvist, O Zettervall, G Öberg and B Simonsson
  Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy+ G-CSF in patients with chronic myelogenous leukemia in first chronic phase
  Leukemia and Lymphoma, 2006, 47(9), 1768-1773.
 Web of Science® Times Cited: 1

M Merup, V Lazarevic, H Nahi, B Andreasson, Claes Malm, L Nilsson, M Brune, K LeBlanc, J Kutti and G Birgegard
  Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens
  British Journal of Haematology, 2006, 135(3), 367-373.
 Web of Science® Times Cited: 30

Gunnar Juliusson, Niklas Theorin, Karin Karlsson, U Frödin and Claes Malm
  Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: Influence of Campath dose on lymphoid recovery, mixed chimerism and survival
  Bone Marrow Transplantation, 2006, 37(5), 503-510.
 Web of Science® Times Cited: 29

Bengt Simonsson, Gunnar Öberg, Mats Björeman, Magnus Björkholm, Jan Carneskog, Karin Karlsson, Gösta Gahrton, Gunnar Grimfors, Robert Hast, Hans Karle, Olle Linder, Per Ljungman, Johan L Nielsen, Jonas Nilsson, Eva Löfvenberg, Claes Malm, Karin Olsson, Ulla Olsson-Strömberg, Christer Paul, Leif Stenke, Jesper Stentoft, Ingemar Turesson, Ann-Marie Udén, Anders Wahlin, Lars Vilén and Ole Weis-Bjerrum
  Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: Long-term follow-up
  Acta Haematologica, 2005, 113(3), 155-162.
 Web of Science® Times Cited: 14

Ulla Olsson-Strömberg, Bengt Simonsson, Tomas Ahlgren, Magnus Björkholm, Karin Carlsson, Gösta Gahrton, Robert Hast, Eva Löfvenberg, Olle Linder, Per Ljungman, Claes Malm, Christer Paul, Stig Rödjer, Ingemar Turesson, Ann-Mari Udén, Anders Wahlin, Andreas Killander, Bengt Wadman, Jan Westin, Olle Vikrot, Olle Zettervall and Gunnar Öberg
  Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival
  The Hematology Journal, 2004, 5(6), 462-466.
 Web of Science® Times Cited: 4

Gunnar Juliusson, Karin Karlsson, Claes Malm, U Frödin, AS Mollen, G Backström and Peter Söderkvist
  Adjusted conditioning for allogeneic transplantation in a single center setting: Mixed chimerism heralds relapse
  Leukemia and Lymphoma, 2003, 44(4), 669-679.
 Web of Science® Times Cited: 4

Ulla Axdorph, Leif Stenke, Gunnar Grimfors, Jan Carneskog, Jan Hansen, Olle Linder, Per Ljungman, Eva Löfvenberg, Claes Malm, Bengt Simonsson, Ingemar Turesson, Lars Vilén, Anne-Marie Udén and Magnus Björkholm
  Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase - A report from the Swedish CML Group
  British Journal of Haematology, 2002, 118(4), 1048-1054.
 Web of Science® Times Cited: 12

Helene Hallböök, Bengt Simonsson, Thomas Ahlgren, Magnus Björkholm, Jan Carneskog, Gunnar Grimfors, Robert Hast, Karin Karlsson, Eva Kimby, Richard Lerner, Olle Linder, Mats Linderholm, Eva Löfvenberg, Claes Malm, Per-Gunnar Nilsson, Christer Paul, Leif Stenke, Dick Stockelberg, Ulf Tidefelt, Ingemar Turesson, Ann-Marie Uden-Blome, Lars Vilen, Anders Wahlin, Ingemar Winquist and Bengt Smedmyr
  High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia
  British Journal of Haematology, 2002, 118, 748-754.

Gunnar Juliusson, Karin Karlsson and Claes Malm
  More potent graft-versus-myeloma effect than graft-versus-renal cell cancer effect
  Leukemia and Lymphoma, 2002, 43(11), 2233-2234.
 Web of Science® Times Cited: 1

Johan D Söderholm, Claes Malm, Gunnar Juliusson and Rune Sjödahl
  Long-term endoscopic remission of Crohn disease after autologous stem cell transplantation for acute myeloid leukaemia
  Scandinavian Journal of Gastroenterology, 2002, 37(5), 613-616.
 Web of Science® Times Cited: 20

Gunnar Juliusson, Fredrik Celsing, Ingemar Turesson, Stig Lenhoff, Magnus Adriansson and Claes Malm
  Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
  British Journal of Haematology, 2000, 109(1), 89-96.
 Web of Science® Times Cited: 186

Conference Articles

Satu Mustjoki, Johan Richter, Gisela Barbany, Hans Ehrencrona, Ingunn Dybedal, Thoas Fioretos, Tobias Gedde-Dahl, Bjorn Gjertsen, Randi Hovland, Sari E Jalkanen, Dag Josefsen, Perttu Koskenvesa, Carin Lassen, Kirsi Latvala, Waleed Majeed, Claes Malm, Berit Markevarn, Ali Mosfegh, Lotta Ohm, Tor Olofsson, Ulla Olsson-Stromberg, Katrin Rapakko, Karil Remes, Jesper Stentoft, Leif Stenke, Merja Suominen, Sara Thunberg, Ole Weiss Bjerrum, Bengt Simonsson, Kimmo Porkka and Henrik Hjorth-Hansen
  Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+Progenitor Cell but Not At the CD34+CD38-Stem Cell Level: Results From Randomized NordCML006 Study in BLOOD, vol 118, issue 21, pp 356-356
  BLOOD, 2011.


Satu Mustjoki, Johan Richter, Gisela Barbany, Ingunn Dybedal, Thoas Fioretos, Tobias Gedde Dahl, Bjorn T Gjertsen, Randi Hovland, Sari Jalkanen, Dag Josefsen, Perttu Koskenvesa, Carin Lassen, Kirsi Latvala, Waleed Majeed, Claes Malm, Berit Markevarn, Ali Moshfegh, Lotta Ohm, Tor Olofsson, Ulla Olsson Stromberg, Katrin Rapakko, Kari Remes, Jesper Stentoft, Leif Stenke, Merja Suominen, Sara Thunberg, Ole Weiss Bjerrum, Bengt Simonsson, Kimmo Porkka and Henrik Hjorth Hansen
  The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study
  BLOOD vol 116, issue 21 (ISSN 0006-4971), 2010.


M Höglund, M Bjoreman, M Björkholm, M Brune, M Ekblom, K Hellström, S Lehmann, P Ljungman, Claes Malm, B Markevarn, F Sandin, L Stenke, H Wadenvik, A Wahlin, J Richter and B Simonsson
  REAL WORLD DATA ON CHRONIC MYELOID LEUKEMIA - A REPORT FROM THE SWEDISH POPULATION BASED CML-REGISTRY in HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, vol 95, issue , pp 337-338
  HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010.


 Web of Science® Times Cited: 1

B Simonsson, M Gedde-Dahl, M Markevarn, P Remes, R Stentoft, S Almqvist, T Bjoreman, V Flogegard, U Hallman, L Koskenveesa, A Lindblom, Claes Malm, S Mustjoki, K Myhr-Eriksson, A Rasanen, M Sinisalo, R Sippola, A Sjalander, U Stromberg, O Weiss Bjerrum, H Ehrencrona, F Gruber, V Kairisto, F Sandin, A Nagler, J Lanng Nielsen, H Hjorth-Hansen and K Porkka
  MAJOR MOLECULAR RESPONSE RATE AT ONE YEAR IS HIGHER IF PEGYLATED INTERFERON ALPHA-2B IS ADDED TO IMATINIB IN NON-HR CHRONIC MYELOID LEUKEMIA PATIENTS IN IMATINIB INDUCED COMPLETE HEMATOLOGICAL REMISSION in HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, vol 95, issue , pp 457-457
  HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010.


 Web of Science® Times Cited: 2

A Nagler, M Labopin, A Shimoni, G Mufti, J J Cornelissen, D Blaise, J J W M Janssen, N Milpied, L Vindelov, E Petersen, J Gribben, A Bacigalupo, Claes Malm, D Niederwieser, G Socie, R Arnold, P Brown, H Goker, M Mohty and V Rocha
  Mobilized peripheral blood stem cells compared with bone marrow for related reduced-intensity transplantation in acute myeloid leukaemia in complete remission: a retrospective analysis from the ALWP of EBMT in BONE MARROW TRANSPLANTATION, vol 45, issue , pp S21-S22
  BONE MARROW TRANSPLANTATION, 2010.


Bengt Simonsson, Tobias Gedde-Dahl, Berit Markevarn, Kari Remes, Jesper Stentoft, Anders Almqvist, Mats Bjoreman, Max Flogegard, Heikki Hallman, Perttu Koskenvesa, Anders Lindblom, Claes Malm, Satu Mustjoki, Kristina Myhr-Eriksson, Anu Rasanen, Marjatta Sinisalo, Risto Sippola, Anders Sjalander, Ulla Stromberg, Ole Weiss Bjerrum, Hans Ehrencrona, Franz Gruber, Veli Kairisto, Karin Olsson, Arnon Nagler, Johan Lanng Nielsen, Henrik Hjorth-Hansen and Kimmo Porkka
  A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy. in BLOOD, vol 114, issue 22, pp 1269-1270
  BLOOD, 2009.


Mohamad Mohty, Myriam Labopin, Nadezda Basara, Jan J Cornelissen, Reza Tabrizi, Claes Malm, Jose Antonio Perez Simon, Arnon Nagler, Nicolaus Kroger, Bernard Rio, Rodrigo Martino, Matthias Eder, Karin Bilger, Donald W W Bunjes, Gerard Socie, Emmanuelle Polge and Vanderson Rocha
  Association Between the Hematopoietic Cell Transplantation-Specific Comorbidity Index (CI) and Non-Relapse Mortality (NRM) After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1) in BLOOD, vol 114, issue 22, pp 270-270
  BLOOD, 2009.


 Web of Science® Times Cited: 2

Frederic Baron, Myriam Labopin, Mohamad Mohty, Nadezda Basara, Dietger Niederwieser, Noel-Jean Milpied, J J Cornelissen, Claes Malm, Henrik Sengeloev, Didier Blaise, Jeroen J W M Janssen, Eefke Petersen, Gerard Socie and Vanderson Rocha
  Graft-Versus-Leukemia (GVL) Effect After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Treatment for Acute Myeloid Leukemia (AML): a Survey From the Acute Leukemia Working Party of the EBMT in BLOOD, vol 114, issue 22, pp 1284-1285
  BLOOD, 2009.


Gunnar Juliusson, K Karlsson, U Frodin, G Backstrom and Claes Malm
  Subcutaneous Campath1H instead of thymoglobulin in nonmyeloablative allogeneic transplantation: Reduced acute toxicity, but delayed lymphocyte recovery leading to more mixed chimerism, more fatal infections and impaired long-term survival
  Blood, 2002.


* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.